Literature DB >> 30004908

Update on epidemiologic considerations and treatment trends in testicular cancer.

Solomon L Woldu1, Aditya Bagrodia.   

Abstract

PURPOSE OF REVIEW: We aim to give an overview of the epidemiology and treatment trends of testicular germ cell tumors (TGCTs), with an emphasis on recent trends. RECENT
FINDINGS: The incidence of TGCT appears to be increasing, particularly in developed countries, although the reasons are not well understood. There is evidence of racial differences in predisposition to TGCT, with white men having highest risk and men of African or Asian descent having lower risk. In the United States, the incidence of TGCT among Hispanics appears to be rising most quickly. A recent genomic analysis indicates there is no highly penetrant major TGCT susceptibility gene. Incorporation of multidisciplinary care has led to excellent long-term cure rates; however, access to care and insurance remains barriers in young men. Recent treatment trends have centered on maximizing oncologic outcomes while minimizing long-term morbidity.
SUMMARY: Emerging population-level data provide critical insight into the evolving demographics of TGCT, which may allow for elucidation of biologic and environmental determinants of TGCT. Further, identification of socioeconomic barriers to excellent clinical outcomes will allow for targeted interventions to patients with unique demographic and socioeconomic considerations. Treatment trend analyses suggest that the field is moving toward minimizing treatment-related morbidity.

Entities:  

Mesh:

Year:  2018        PMID: 30004908      PMCID: PMC6134403          DOI: 10.1097/MOU.0000000000000532

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  79 in total

1.  Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

Authors:  R Timothy D Oliver; Graham M Mead; Gordon J S Rustin; Johnathan K Joffe; Nina Aass; Robert Coleman; Rhian Gabe; Philip Pollock; Sally P Stenning
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.

Authors:  S B Saxman; D Finch; R Gonin; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene.

Authors:  Kevin Litchfield; Chey Loveday; Max Levy; Darshna Dudakia; Elizabeth Rapley; Jeremie Nsengimana; D Tim Bishop; Alison Reid; Robert Huddart; Peter Broderick; Richard S Houlston; Clare Turnbull
Journal:  Eur Urol       Date:  2018-02-09       Impact factor: 20.096

4.  One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.

Authors:  T Tandstad; O Ståhl; U Håkansson; O Dahl; H S Haugnes; O H Klepp; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; E Cavallin-Ståhl; U Stierner; R Wahlquist; N Wall; G Cohn-Cedermark
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

5.  Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.

Authors:  Mahmut Gumus; Ahmet Bilici; Hatice Odabas; Bala Basak Oven Ustaalioglu; Nurten Kandemir; Umut Demirci; Sener Cihan; Ibrahim Vedat Bayoglu; Turkan Ozturk; Esma Turkmen; Zurat Urakci; Mehmet Metin Seker; Yusuf Gunaydin; Fatih Selcukbiricik; Nedim Turan; Alper Sevinc
Journal:  World J Urol       Date:  2016-11-03       Impact factor: 4.226

6.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

7.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Authors:  R T D Oliver; M D Mason; G M Mead; H von der Maase; G J S Rustin; J K Joffe; R de Wit; N Aass; J D Graham; R Coleman; S J Kirk; S P Stenning
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

Review 8.  Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes.

Authors:  P Giannatempo; T Greco; L Mariani; N Nicolai; S Tana; E Farè; D Raggi; L Piva; M Catanzaro; D Biasoni; T Torelli; S Stagni; B Avuzzi; M Maffezzini; G Landoni; F De Braud; A M Gianni; G Sonpavde; R Salvioni; A Necchi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

9.  Current Practice Patterns Surrounding Fertility Concerns in Stage I Seminoma Patients: Survey of United States Radiation Oncologists.

Authors:  Carl M Post; Aditya Jain; Catherine Degnin; Yiyi Chen; Mike Craycraft; Arthur Y Hung; Jerry J Jaboin; Charles R Thomas; Timur Mitin
Journal:  J Adolesc Young Adult Oncol       Date:  2018-01-16       Impact factor: 2.223

10.  Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility.

Authors:  Kevin Litchfield; Max Levy; Darshna Dudakia; Paula Proszek; Claire Shipley; Sander Basten; Elizabeth Rapley; D Timothy Bishop; Alison Reid; Robert Huddart; Peter Broderick; David Gonzalez de Castro; Simon O'Connor; Rachel H Giles; Richard S Houlston; Clare Turnbull
Journal:  Nat Commun       Date:  2016-12-20       Impact factor: 14.919

View more
  1 in total

Review 1.  Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors.

Authors:  Ratnakar Singh; Zeeshan Fazal; Sarah J Freemantle; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.